MARD

Know Labs’ Non-Invasive Glucose Monitor Achieves 11.1% MARD in Latest Clinical Research Study

Retrieved on: 
Wednesday, March 6, 2024

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced interim results from its most recent clinical research study.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced interim results from its most recent clinical research study.
  • Dr. Virend K. Somers of the Mayo Clinic serves as an author and co-investigator on the clinical research protocol.
  • “Despite significant efforts in the development of non-invasive blood glucose monitoring solutions, delivering a highly accurate, economical, FDA-cleared non-invasive continuous glucose monitor (CGM) still remains to be seen.
  • On the held-out test dataset, blood glucose was estimated with a MARD of 11.1 ± 2.1% relative to venous blood.

Spiden Announces Breakthrough in Non-Invasive Glucose Monitoring, Adds Key Executive Hires and Secures $15m in Additional Funding

Retrieved on: 
Saturday, January 6, 2024

Spiden's latest non-invasive glucose measurement campaignSpiden's latest glucose measurement data comparing its non-invasive portable device (y-axis) with the invasive gold-standard (x-axis), illustrated in the Clarke Error Grid.

Key Points: 
  • Spiden's latest non-invasive glucose measurement campaignSpiden's latest glucose measurement data comparing its non-invasive portable device (y-axis) with the invasive gold-standard (x-axis), illustrated in the Clarke Error Grid.
  • Spiden has achieved remarkable scientific progress in non-invasive glucose sensing.
  • This achievement is the latest important step towards a calibration-free and miniaturized device for non-invasive glucose monitoring.
  • A larger funding round is planned for H2 in 2024, which will provide Spiden with sufficient capital to bring its product to market and become profitable.

GLUCOTRACK ANNOUNCES EARLY ACCURACY DATA FOR ITS IMPLANTABLE CONTINUOUS GLUCOSE MONITOR

Retrieved on: 
Tuesday, January 2, 2024

The Company announces the successful completion of their first preclinical study of the implantable CBGM.

Key Points: 
  • The Company announces the successful completion of their first preclinical study of the implantable CBGM.
  • In comparison, many continuous glucose monitoring (CGM) systems measure glucose in the interstitial fluid, which lags behind blood glucose.
  • The Company also announces a second milestone: the commencement of long-term preclinical testing on the implantable CBGM.
  • GlucoTrack is committed to commercializing an implantable CBGM with a long-term sensor life, no requirement for an additional wearable component, and a once-only calibration event.

SIBIONICS Achieves Milestone: Receiving CE Mark for Its Groundbreaking GS1 Continuous Glucose Monitoring System

Retrieved on: 
Wednesday, November 1, 2023

SHENZHEN, China, Nov. 1, 2023 /PRNewswire/ -- SIBIONICS, the world's third-largest Continuous Glucose Monitoring System (CGM) brand, is delighted to announce that it has received the CE Mark for its revolutionary GS1 CGM.

Key Points: 
  • SHENZHEN, China, Nov. 1, 2023 /PRNewswire/ -- SIBIONICS, the world's third-largest Continuous Glucose Monitoring System (CGM) brand, is delighted to announce that it has received the CE Mark for its revolutionary GS1 CGM.
  • Founded in 2015, SIBIONICS boasts a workforce exceeding 700 individuals, with over 40% actively engaged in research and development efforts.
  • The SIBIONICS GS1 CGM offers users 14 days of calibration-free continuous glucose monitoring solution, empowering them with the capability to transmit glucose data to their monitoring devices or mobile applications and generate professional AGP reports.
  • Starting today, SIBIONICS GS1 CGM products will gradually become available for pre-sales in EU countries, the UK, and other European countries.

SIBIONICS Achieves Milestone: Receiving CE Mark for Its Groundbreaking GS1 Continuous Glucose Monitoring System

Retrieved on: 
Wednesday, November 1, 2023

SHENZHEN, China, Nov. 1, 2023 /PRNewswire/ -- SIBIONICS, the world's third-largest Continuous Glucose Monitoring System (CGM) brand, is delighted to announce that it has received the CE Mark for its revolutionary GS1 CGM.

Key Points: 
  • SHENZHEN, China, Nov. 1, 2023 /PRNewswire/ -- SIBIONICS, the world's third-largest Continuous Glucose Monitoring System (CGM) brand, is delighted to announce that it has received the CE Mark for its revolutionary GS1 CGM.
  • Founded in 2015, SIBIONICS boasts a workforce exceeding 700 individuals, with over 40% actively engaged in research and development efforts.
  • The SIBIONICS GS1 CGM offers users 14 days of calibration-free continuous glucose monitoring solution, empowering them with the capability to transmit glucose data to their monitoring devices or mobile applications and generate professional AGP reports.
  • Starting today, SIBIONICS GS1 CGM products will gradually become available for pre-sales in EU countries, the UK, and other European countries.

Nemaura Medical Completes 100 Patient Study for sugarBEAT® 24-hour Wear and Reports Interim Results

Retrieved on: 
Monday, September 11, 2023

The Company has previously received CE approval in Europe, and SFDA (Saudi Food and Drug Authority) approval for its sugarBEAT® glucose sensor for a wear period of 14 hours.

Key Points: 
  • The Company has previously received CE approval in Europe, and SFDA (Saudi Food and Drug Authority) approval for its sugarBEAT® glucose sensor for a wear period of 14 hours.
  • This study was designed to evaluate several factors, including the possibility of increasing the wear period to up to 24 hours, evaluating the possibility of auto-calibration, and different methods of application of the device to the skin.
  • The Company reports interim data from a first cohort comprising 25 patients, on a single day sensor wear.
  • The results indicate that a 24-hour sensor wear period using a single sensor is possible, which is expected to allow users to monitor their glucose fluctuations overnight.

Leaders Gather for The 3rd Global Food Security & Sustainability Summit

Retrieved on: 
Thursday, August 31, 2023

DA NANG, VIETNAM, Aug 31, 2023 - (ACN Newswire) - Fifteen leaders gathered for The 3rd Global Food Security & Sustainability Summit in Danang, Vietnam on August 29, 2023.

Key Points: 
  • DA NANG, VIETNAM, Aug 31, 2023 - (ACN Newswire) - Fifteen leaders gathered for The 3rd Global Food Security & Sustainability Summit in Danang, Vietnam on August 29, 2023.
  • The summit focused on scaling up climate resilience and transforming food value chains to mitigate ESG risks, attracting key stakeholders, policymakers, government institutions, investors and United Nations bodies.
  • Mr. Remi Nono Womdim, Representative of the Food and Agriculture Organization of the United Nations (FAO) in Viet Nam, presented a global perspective in "Averting A Global Food Crisis - What Must Be Done?"
  • The summit brought new perspectives and opened conversations to effectively tackle the imminent challenges addressed in food security and sustainability.

Apollon and MIT Commence Collaboration to Develop Continuous Non-Invasive Glucose Monitoring Technology

Retrieved on: 
Monday, August 21, 2023

Dr. Peter So, Professor of Mechanical and Biological Engineering and Director of the MIT LBRC, and Dr. Jeonwoong Kang of the Department of Mechanical Engineering will lead the collaboration.

Key Points: 
  • Dr. Peter So, Professor of Mechanical and Biological Engineering and Director of the MIT LBRC, and Dr. Jeonwoong Kang of the Department of Mechanical Engineering will lead the collaboration.
  • As a result of Apollon's expertise in Raman diagnostics and spectrometer miniaturization, MIT will invite Dr. Youngkyu Kim of Apollon as a visiting scientist.
  • Dr. Kang published a paper in the prestigious journal Science Advances in 2020 that directly measured glucose concentration without drawing blood by irradiating the skin with laser light.
  • It was funded by the National Institutes of Health and Samsung Advanced Institute of Technology.

HAGAR Unveils New Clinical Data on Groundbreaking GWave Technology, Closing Round C Funding

Retrieved on: 
Thursday, August 10, 2023

He unveiled the data which included results in hypoglycemic levels demonstrating GWave’s unmatched accuracy and scalability of the product for the wellness and diabetic space.

Key Points: 
  • He unveiled the data which included results in hypoglycemic levels demonstrating GWave’s unmatched accuracy and scalability of the product for the wellness and diabetic space.
  • Employing its novel RF wave technology, GWave non-invasively and accurately monitors blood glucose levels in real time.
  • An innovative feature of the GWave device is its automated alert system, designed to inform users of any significant glucose level fluctuations.
  • In an impressive outcome, Dr. Hirsch lowered his glucose levels from 180 to 46 while GWave accurately monitored his blood glucose levels.

Know Labs Demonstrates Improved Accuracy of Machine Learning Model for Non-Invasive Glucose Monitor

Retrieved on: 
Wednesday, July 26, 2023

Know Labs, Inc. (NYSE American: KNW) today announced results from a new study titled, “ Novel data preprocessing techniques in an expanded dataset improve machine learning model accuracy for a non-invasive blood glucose monitor .” The study demonstrates that continued algorithm refinement and more high-quality data improved the accuracy of Know Labs’ proprietary Bio-RFID sensor technology, resulting in an overall Mean Absolute Relative Difference (MARD) of 11.3%.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW) today announced results from a new study titled, “ Novel data preprocessing techniques in an expanded dataset improve machine learning model accuracy for a non-invasive blood glucose monitor .” The study demonstrates that continued algorithm refinement and more high-quality data improved the accuracy of Know Labs’ proprietary Bio-RFID sensor technology, resulting in an overall Mean Absolute Relative Difference (MARD) of 11.3%.
  • As with all Know Labs’ previous research, this study was designed to assess the ability of the Bio-RFID sensor to non-invasively and continuously quantify blood glucose, using the Dexcom G6® continuous glucose monitor (CGM) as a reference device.
  • With this method, Know Labs was able to predict blood glucose in the test set – the dataset that provides a blind evaluation of model performance – with a MARD of 11.3%.
  • For 2023, Know Labs remains focused on refinement and external validation of its technology and contributing to its growing body of peer-reviewed evidence, which can be found at www.knowlabs.co/research-and-validation .